Drug
Alxn2220
Alxn2220: highest development phase Phase 3, developed by Alexion. 2 trial records tracked on RxWires.
- Highest phase
- Phase 3
- Developer
- Alexion
Trials
| Drug | Phase | Indication |
|---|---|---|
| ALXN2220 NCT06183931 | Phase 3 | Transthyretin Amyloid Cardiomyopathy |
| ALXN2220 NCT07789483 | Phase 3 | Transthyretin Amyloid Cardiomyopathy (ATTR-CM) |
Latest
No recent events.
Follow Alxn2220 on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.